Jalra

उत्पाद अवलोकन

About Jalra

Jalra is a medication containing the active ingredient Vildagliptin. Vildagliptin, sold under the brand name Galvus among others, is an oral anti-hyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress….

Key Benefits & Uses

• Used for: Vildagliptin, sold under the brand name Galvus among others, is an oral anti-hyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor.
• Used for: Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and.
• Use only as directed on the product label or by a healthcare professional.

Active Ingredient & Action

Vildagliptin, the active ingredient in Jalra, is the pharmacologically active substance of this product. Its clinical use follows the authorised labelling for Vildagliptin-containing medicines. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Jalra. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Jalra for extended periods without medical advice.